Earnings ·
Tyra Biosciences reports Q3 net loss of $51.1M and highlights Phase 2 SURF302 results
TYRATyra Biosciences, Inc.
Tyra Biosciences reported a third-quarter net loss of $51.1 million, compared to $29.9 million in the prior-year period, driven by higher research and development expenses of $43.1 million as clinical trials for dabogratinib advance. The company also highlighted initial Phase 2 SURF302 results showing a 79% overall response rate for oral dabogratinib in FGFR3-altered low-grade IR NMIBC patients, alongside the completion of a $400 million equity financing that provides a cash runway through 2030. Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology.